What other multi-cancer early detection tests are currently available?

Currently available or recently launched MCED tests include: Galleri (Grail Inc.) — cfDNA methylation, blood draw, prescription required, ~$949, 16.8% Stage I sensitivity; Shield (Exact Sciences) — cfDNA methylation, blood draw, FDA-approved for colorectal only, ~$895; CancerSEEK (Johns Hopkins/Exact Sciences, developmental) — combines cfDNA mutations with protein markers; OncoSeek (Exact Sciences, in development) — protein biomarker panel; PanSeer (BGI Genomics) — DNA methylation, primarily studied in China. OncuraKit is the only urine-based MCED test in this market, the only amplification-free single-molecule test, and the only test reporting zero data overlap. Most competitors require blood draws and prescriptions; OncuraKit requires neither.